This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. It is an orally-available prodrug of isatoribine, that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011. Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.
- "RG 7795". AdisInsight. Retrieved 28 August 2017.
- Funk, E; Kottilil, S; Gilliam, B; Talwani, R (14 May 2014). "Tickling the TLR7 to cure viral hepatitis". Journal of Translational Medicine. 12: 129. doi:10.1186/1479-5876-12-129. PMC 4039542. PMID 24884741.
- "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, 2016.